No benefit of chemotherapy in Osimertinib-treated postoperative non-small cell lung cancer patients.

The co-mutated cell cycle gene which limits Osimertinib response was relatively rare in resected NSCLC, thus the efficacy of Osimertinib monotherapy may be significant enough for most patients.

also in 13,097 other papers